"First-in-human clinical trial, double blind, randomized with placebo, open for the six first patients (dose ranging), to evaluate the safety and efficacy of intracoronary infusion of allogeneic human cardiac stem cells (CSCs) in patients with Acute Myocardial Infarction and Left Ventricular Dysfunction." - CAREMI

Trial Profile

"First-in-human clinical trial, double blind, randomized with placebo, open for the six first patients (dose ranging), to evaluate the safety and efficacy of intracoronary infusion of allogeneic human cardiac stem cells (CSCs) in patients with Acute Myocardial Infarction and Left Ventricular Dysfunction." - CAREMI

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs CTX 101 (Primary)
  • Indications Left ventricular dysfunction; Myocardial infarction
  • Focus Adverse reactions; First in man
  • Acronyms CAREMI
  • Sponsors Coretherapix
  • Most Recent Events

    • 23 Jun 2017 According to a TiGenix media release, this trial trial has benefited from the support of the CAREMI consortium (Grant Number 242038) funded by the Seventh Framework Programme of the European Commission under the coordination of the Centro Nacional the Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Biotecnologia and the participation of research institutions and companies from nine EU countries.
    • 13 Mar 2017 According to a TiGenix NV media release, full data from this trial will be presented at an upcoming medical congress.
    • 13 Mar 2017 Top-line results published in a TiGenix NV media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top